TAK-701, a Humanized Monoclonal Antibody to Hepatocyte Growth Factor, Reverses Gefitinib Resistance Induced by Tumor-Derived HGF in Non–Small Cell Lung Cancer with an EGFR Mutation

Most non–small cell lung cancer (NSCLC) tumors with an activating mutation of the epidermal growth factor receptor (EGFR) are initially responsive to EGFR tyrosine kinase inhibitors (TKI) such as gefitinib but ultimately develop resistance to these drugs. Hepatocyte growth factor (HGF) induces EGFR-TKI resistance in NSCLC cells with such a mutation. We investigated strategies to overcome gefitinib resistance induced by HGF. Human NSCLC cells with an activating EGFR mutation (HCC827 cells) were engineered to stably express HGF (HCC827-HGF cells). HCC827-HGF cells secreted large amounts of HGF and exhibited resistance to gefitinib in vitro to an extent similar to that of HCC827 GR cells, in which the gene for the HGF receptor MET is amplified. A MET-TKI reversed gefitinib resistance in HCC827-HGF cells as well as in HCC827 GR cells, suggesting that MET activation induces gefitinib resistance in both cell lines. TAK-701, a humanized monoclonal antibody to HGF, in combination with gefitinib inhibited the phosphorylation of MET, EGFR, extracellular signal-regulated kinase, and AKT in HCC827-HGF cells, resulting in suppression of cell growth and indicating that autocrine HGF-MET signaling contributes to gefitinib resistance in these cells. Combination therapy with TAK-701 and gefitinib also markedly inhibited the growth of HCC827-HGF tumors in vivo. The addition of TAK-701 to gefitinib is a promising strategy to overcome EGFR-TKI resistance induced by HGF in NSCLC with an activating EGFR mutation. Mol Cancer Ther; 9(10); 2785–92. ©2010 AACR.

[1]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  K. Sugio,et al.  Acquired resistance to gefitinib: the contribution of mechanisms other than the T790M, MET, and HGF status. , 2010, Lung cancer.

[3]  B. Zbar,et al.  Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. , 2002, The Journal of clinical investigation.

[4]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[5]  N. J. McNally,et al.  United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for the Welfare of Animals in Experimental Neoplasia (Second Edition). , 1998, British Journal of Cancer.

[6]  P. Workman,et al.  UKCCCR guidelines for the welfare of animals in experimental neoplasia. , 1988, British Journal of Cancer.

[7]  K. Tashiro,et al.  Molecular cloning and expression of human hepatocyte growth factor , 1989, Nature.

[8]  G. Watanabe,et al.  Crosstalk to Stromal Fibroblasts Induces Resistance of Lung Cancer to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors , 2009, Clinical Cancer Research.

[9]  M. Fukuoka,et al.  Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification. , 2007, Cancer research.

[10]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[11]  Y. Yatabe,et al.  Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. , 2008, Cancer research.

[12]  D. Yee,et al.  Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. , 2008, The Journal of clinical investigation.

[13]  W. Birchmeier,et al.  Met, metastasis, motility and more , 2003, Nature Reviews Molecular Cell Biology.

[14]  William Pao,et al.  MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib , 2007, Proceedings of the National Academy of Sciences.

[15]  S. Gabriel,et al.  EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.

[16]  R. Ball,et al.  IMMUNOREACTIVITY FOR HEPATOCYTE GROWTH FACTOR/SCATTER FACTOR AND ITS RECEPTOR, met, IN HUMAN LUNG CARCINOMAS AND MALIGNANT MESOTHELIOMAS , 1996, The Journal of pathology.

[17]  Kaoru Tanaka,et al.  SRPX2 is overexpressed in gastric cancer and promotes cellular migration and adhesion , 2009, International journal of cancer.

[18]  Luca Toschi,et al.  Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. , 2010, Cancer cell.

[19]  A. Marcus,et al.  Hepatocyte growth factor is predominantly expressed by the carcinoma cells in non-small-cell lung cancer. , 2001, Human pathology.

[20]  E. Hudson,et al.  Met and hepatocyte growth factor/scatter factor expression in human gliomas. , 1997, Cancer research.

[21]  Toshikazu Nakamura,et al.  Hepatocyte growth factor and the Met system as a mediator of tumor–stromal interactions , 2006, International journal of cancer.

[22]  D. Brewster,et al.  Trends in cancer incidence and mortality in Scotland: description and possible explanations. , 1998, British Journal of Cancer.

[23]  T. Nakamura,et al.  Hepatocyte growth factor/scatter factor is an autocrine factor for human normal bronchial epithelial and lung carcinoma cells. , 1993, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[24]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[25]  R. Salgia,et al.  Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. , 2002, Cytokine & growth factor reviews.

[26]  M. Fukuoka,et al.  Identification of c-Src as a Potential Therapeutic Target for Gastric Cancer and of MET Activation as a Cause of Resistance to c-Src Inhibition , 2010, Molecular Cancer Therapeutics.

[27]  B. Elliott,et al.  Coexpression of hepatocyte growth factor and receptor (Met) in human breast carcinoma. , 1996, The American journal of pathology.

[28]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[29]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[30]  J. Rubin,et al.  Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. , 1991, Science.

[31]  G. Michalopoulos,et al.  Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. , 1991, Oncogene.